Opticospinal Multiple Sclerosis

02/01/2003 - "This form of MS generally has a higher age at onset and a higher female to male ratio than conventional MS. Opticospinal MS is also characterised by frequent relapses, severe disability, few brain lesions visible on MRI, long lesions extending over many vertebral segments visible on spinal-cord MRI, pleocytosis and an absence of oligoclonal bands in the CSF, and a pronounced shift in the responses of T-helper-1 and T-cytotoxic-1 cells throughout relapse and remission phases. "
11/01/2007 - "Recurrent NMO has been described as optic-spinal multiple sclerosis (OSMS) in Japan, but it has been known that NMO has distinct clinical and laboratory findings (female preponderance, severe disability, longitudinally extensive myelitis, CSF-pleocytosis, negative oligoclonal IgG bands, etc) from those in typical MS. In addition, anti-aquaporin-4 (AQP4) antibody and loss of AQP4 in the active perivascular NMO lesions with deposition of immunoglobulins and activated complements were recently found to be NMO-specific, strongly suggesting that NMO is a clinical entity that should be separated from MS. In accordance with these unique features of NMO, different therapeutic responses between NMO and MS have been observed, that is, interferon-beta, a disease-modifying therapy (DMT) for MS, is less effective in NMO, while long-term administration of corticosteroid and immunosuppressive agents reduce relapses of NMO. "

09/01/1999 - "HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies."
02/01/2006 - "HLA-dPB1*0501 is not uniquely associated with opticospinal multiple sclerosis in Japanese patients. "
09/01/1999 - "The frequency of the HLA-DPB1*0501 allele was found to be significantly greater in opticospinal multiple sclerosis (93%) than in healthy controls (63%, corrected P value = 0.0091 and relative risk = 7.9), but not in Western type multiple sclerosis (66%) or spinal multiple sclerosis (82%). "
09/01/1999 - "The marked differences in the clinical and MRI findings as well as in the immunogenetic backgrounds between the opticospinal multiple sclerosis and Western-type multiple sclerosis together suggest that HLA-DPB1*0501-associated opticospinal multiple sclerosis is a distinct subtype of multiple sclerosis."
08/01/2003 - "Conventional MS in Japanese is, like MS in Caucasians, associated with HLA-DRB1*1501 whereas opticospinal MS is associated with HLA-DPB1*0501. "

07/15/2004 - "To address the immune mechanism sustaining interferon beta (IFNbeta) efficacy in multiple sclerosis (MS), we longitudinally analyzed expressions of IFN-gamma, IL-4, IL-5 and IL-13 in CD4+ T cells and CD8+ T cells in 22 Japanese MS patients (16 patients with conventional MS and 6 with opticospinal MS) undergoing IFNbeta using flow cytometry. "
11/01/2007 - "Recurrent NMO has been described as optic-spinal multiple sclerosis (OSMS) in Japan, but it has been known that NMO has distinct clinical and laboratory findings (female preponderance, severe disability, longitudinally extensive myelitis, CSF-pleocytosis, negative oligoclonal IgG bands, etc) from those in typical MS. In addition, anti-aquaporin-4 (AQP4) antibody and loss of AQP4 in the active perivascular NMO lesions with deposition of immunoglobulins and activated complements were recently found to be NMO-specific, strongly suggesting that NMO is a clinical entity that should be separated from MS. In accordance with these unique features of NMO, different therapeutic responses between NMO and MS have been observed, that is, interferon-beta, a disease-modifying therapy (DMT) for MS, is less effective in NMO, while long-term administration of corticosteroid and immunosuppressive agents reduce relapses of NMO. "

11/01/2021 - "Biomarkers have improved the classification of autoimmune inflammatory disorders, including optic neuritis (ON) as a frequent presentation of multiple sclerosis, neuromyelitis spectrum disorders, MOG antibody-related disease (MOGAD), and opticospinal multiple sclerosis (OSMS). "
03/01/2009 - "A variety of idiopathic inflammatory disorders such as Japanese form of optic spinal MS, recurrent myelitis, and recurrent optic neuritis have been brought under the umbrella of neuromyelitis spectrum disorders because of the association with NMO-IgG. Complete transverse myelitis accompanied by longitudinally extensive transverse myelitis which is seronegative for this biomarker has also been reported from several countries including Japan, Australia, and India. "

02/01/2007 - "[Case of opticospinal multiple sclerosis showing phenotype change to conventional type induced by interferon beta-1b]."
02/22/2005 - "Interferon beta-1b (IFNB-1b) 250 microg significantly reduced relapse rates and change in MRI lesion area in Japanese patients with relapsing-remitting multiple sclerosis, and seemed to be comparably effective in optic-spinal multiple sclerosis (MS) and classic MS. The response to treatment with IFNB-1b in Japanese patients with MS suggests that a common pathogenesis and underlying genetic characteristics are shared with white patients."

01/01/2011 - "Therapeutic efficacy of interferon β-1b in Japanese patients with optic-spinal multiple sclerosis."
01/01/2011 - "Since patients with optic neuritis and myelitis have often been diagnosed with "optic-spinal MS (OSMS)" in Asia, it was obscure whether "OSMS" is synonymous with NMO or includes both NMO and MS. Interferon β (IFNβ)-1a and -1b are used as the first-line disease-modifying therapy for MS. However, some neurologists have been reluctant to use IFNβ to treat patients with optic-spinal symptoms, because IFNβ therapy is not efficacious in NMO. "

11/01/2007 - "Recurrent NMO has been described as optic-spinal multiple sclerosis (OSMS) in Japan, but it has been known that NMO has distinct clinical and laboratory findings (female preponderance, severe disability, longitudinally extensive myelitis, CSF-pleocytosis, negative oligoclonal IgG bands, etc) from those in typical MS. In addition, anti-aquaporin-4 (AQP4) antibody and loss of AQP4 in the active perivascular NMO lesions with deposition of immunoglobulins and activated complements were recently found to be NMO-specific, strongly suggesting that NMO is a clinical entity that should be separated from MS. In accordance with these unique features of NMO, different therapeutic responses between NMO and MS have been observed, that is, interferon-beta, a disease-modifying therapy (DMT) for MS, is less effective in NMO, while long-term administration of corticosteroid and immunosuppressive agents reduce relapses of NMO. "

11/01/2007 - "Recurrent NMO has been described as optic-spinal multiple sclerosis (OSMS) in Japan, but it has been known that NMO has distinct clinical and laboratory findings (female preponderance, severe disability, longitudinally extensive myelitis, CSF-pleocytosis, negative oligoclonal IgG bands, etc) from those in typical MS. In addition, anti-aquaporin-4 (AQP4) antibody and loss of AQP4 in the active perivascular NMO lesions with deposition of immunoglobulins and activated complements were recently found to be NMO-specific, strongly suggesting that NMO is a clinical entity that should be separated from MS. In accordance with these unique features of NMO, different therapeutic responses between NMO and MS have been observed, that is, interferon-beta, a disease-modifying therapy (DMT) for MS, is less effective in NMO, while long-term administration of corticosteroid and immunosuppressive agents reduce relapses of NMO. "

11/01/2007 - "Recurrent NMO has been described as optic-spinal multiple sclerosis (OSMS) in Japan, but it has been known that NMO has distinct clinical and laboratory findings (female preponderance, severe disability, longitudinally extensive myelitis, CSF-pleocytosis, negative oligoclonal IgG bands, etc) from those in typical MS. In addition, anti-aquaporin-4 (AQP4) antibody and loss of AQP4 in the active perivascular NMO lesions with deposition of immunoglobulins and activated complements were recently found to be NMO-specific, strongly suggesting that NMO is a clinical entity that should be separated from MS. In accordance with these unique features of NMO, different therapeutic responses between NMO and MS have been observed, that is, interferon-beta, a disease-modifying therapy (DMT) for MS, is less effective in NMO, while long-term administration of corticosteroid and immunosuppressive agents reduce relapses of NMO. "

02/01/2015 - "Thus, is it possible that the clinical NMOSD-like phenotype associated with MOG-specific antibodies represents a variant of opticospinal MS or ADEM but not AQP4 autoimmunity or NMOSD? "
07/01/2009 - "Antibodies to aquaporin-4 (AQP4) are found in a fraction of Japanese opticospinal multiple sclerosis (OSMS) patients. "
04/15/2011 - "The detection of aquaporin-4 (AQP4) antibodies has broadened the spectrum of the disorder, which now includes limited variants (either recurrent myelitis or optic neuritis), Asian opticospinal MS, and "atypical" forms with brain involvement. "
01/01/2016 - "Antibodies to myelin oligodendrocyte glycoprotein are uncommon in Japanese opticospinal multiple sclerosis."
02/01/2009 - "Of the subjects with opticospinal MS or a history of recurrent transverse myelitis who were seropositive for anti-aquaporin 4 antibodies (approximately 5%), none carried DRB1*15 alleles (P = .008). "

07/15/2004 - "When comparisons with the pretreatment values were made for each subtype of MS, a significant reduction of IFN-gamma+ IL-4- CD4+ T cell percentages was shown in conventional MS (p<0.0001), but not in opticospinal MS. Moreover, when such a comparison was made by the presence or absence of relapse during therapy, a significant reduction of IFN-gamma+ IL-4- CD4+ T cell percentages was observed in MS patients without relapse (p<0.01). "
06/01/2008 - "Large-scale clinical trials have established the clinical efficacy of IFNbeta in reducing relapses and slowing disease progression in relapsing-remitting MS. IFNbeta therapy was shown to be comparably beneficial for opticospinal MS (OSMS) and conventional MS in Japanese. "
01/01/2011 - "Since patients with optic neuritis and myelitis have often been diagnosed with "optic-spinal MS (OSMS)" in Asia, it was obscure whether "OSMS" is synonymous with NMO or includes both NMO and MS. Interferon β (IFNβ)-1a and -1b are used as the first-line disease-modifying therapy for MS. However, some neurologists have been reluctant to use IFNβ to treat patients with optic-spinal symptoms, because IFNβ therapy is not efficacious in NMO. "
12/01/2000 - "T cell vaccination, altered peptide ligand and oral tolerance are possible candidates for specific immune therapy for MS. As in Asians there is such a distinct subtype of MS as HLA-DPB 1 * 0501-associated opticospinal MS, it is important to look for unique immune therapy for opticospinal MS in future."
11/01/2007 - "Recurrent NMO has been described as optic-spinal multiple sclerosis (OSMS) in Japan, but it has been known that NMO has distinct clinical and laboratory findings (female preponderance, severe disability, longitudinally extensive myelitis, CSF-pleocytosis, negative oligoclonal IgG bands, etc) from those in typical MS. In addition, anti-aquaporin-4 (AQP4) antibody and loss of AQP4 in the active perivascular NMO lesions with deposition of immunoglobulins and activated complements were recently found to be NMO-specific, strongly suggesting that NMO is a clinical entity that should be separated from MS. In accordance with these unique features of NMO, different therapeutic responses between NMO and MS have been observed, that is, interferon-beta, a disease-modifying therapy (DMT) for MS, is less effective in NMO, while long-term administration of corticosteroid and immunosuppressive agents reduce relapses of NMO. "

03/01/2011 - "To evaluate clinical outcomes of autologous peripheral blood stem cell transplantation (APBCST) between opticospinal multiple sclerosis (OSMS) and conventional multiple sclerosis (CMS) during disease progressive stage in a Chinese population. "